Therapeutic agents that prevent SOST and DKK1‐inhibition of the Wnt signaling pathway have been previously reported to prevent MM‐induced bone loss and the onset of osteolytic bone lesions.(23, 24) This investigation, however, is the first to define the cellular mechanisms driving improvements in bone volume with the novel anti‐LRP6 antibody, which potentiates Wnt signaling through binding the LRP6 receptor. Here, SOST is linked to Miyoshi myopathy.